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What blood pressure reduction should we expect from renal denervation?
Insights from ofﬁce versus ambulatory pressure reductions in uncontrolled and
blinded placebo-controlled drug trials of 4,121 patients
James P. Howard1, Darrel P. Francis1, Alexandra N. Nowbar1
1Imperial College London, London, United Kingdom
Background: Trials of renal denervation report drops ofw30mmHg in ofﬁce systolic
blood pressure, yet reductions in ambulatory pressures appear to bew3-fold smaller.
It has been claimed this disparity is seen in antihypertensive drug trials. We examine
this ofﬁce-ambulatory discrepancy though meta-analysis of drug trials reporting ofﬁce
and ambulatory pressures.
Methods:We tested the hypothesis that ofﬁce pressure drops overestimate ambulatory
drops by meta-analysis of both one-armed and double-blinded placebo-controlled drug
trials.
Results: DRUG TRIALS: 31 drug trials enrolling 4,121 patients met the criteria.
Ofﬁce blood pressure drop per unit ambulatory pressure drop was 1.46 (95% CI 1.23
to 1.68) in uncontrolled trials, but only 0.96 (95% CI 0.81 to 1.12) for blinded
placebo-controlled trials. DENERVATION: 23 trials enrolling 720 patients were
analysed. Ofﬁce pressure drops were 26.7 mmHg versus controls in open label trials.
Ambulatory pressure drops averaged 15.7 mmHg. No randomized blinded results are
available.P
O
S
T
E
R
SConclusions: In drug trials only unblinded uncontrolled studies demonstrate ofﬁce
pressure drops to be larger than ambulatory drops. The ofﬁce-ambulatory pressure
drop discrepancy in renal denervation trials may therefore be absent from future
double-blinded trials. Persistence of the discrepancy would only be possible if renal
denervation managed to abolish the alerting response, or 'white coat effect', implying
that the alerting response is mediated by the renal sympathetic nerves.
TCT-487
Renal Sympathetic Denervation for Resistant Hypertension in the Real World
Clinical Practice: Results of the Symplicity Venezuelan Registry
Humberto S. Casal1, Carlos A. Collet2, Nusen Beer1, Bruno Burger3, Victor Bellera4,
Carlos Caldera5, Humberto Casal Heredia1, Jose Condado6, Roberto C. Correa7,
Enrique Fermin8, Carlos Galan9, Mauro Herrera5, Pedro Hidalgo10,
Carlos E. Leon11, Juan Simon Muñoz12, Cesar Ochoa13, Aguiar Pedro14,
Victor Rodriguez15, Jose Miguel Torres16, Gabriel Varnagy1,
Jose Robinson Vasquez17
1Hospital de Clinicas Caracas, Caracas, Venezuela, 2Clinica El Avila, Caracas,
Venezuela, 3CMDLT, Caracas, Venezuela, 4La Vina, valencia, Venezuela, 5Instituto
Urologico, Caracas, Venezuela, 6centro medico de caracas, Caracas, Venezuela,
7CentroMedicoCaracas, Caracas, Venezuela, 8Hospital de Clinicas Caracas,
caracas, Venezuela, 9Hospital Clinico Universitario Maracaibo, maracaibo,
Venezuela, 10Clinica Amado, Maracaibo, Venezuela, 11Centro Oncologico,
Barquisimeto, Venezuela, 12La Floresta, Caracas, Venezuela, 13Hospital de Clinicas
Caracas, Caracas, DF, 14La Floresta, caracas, Venezuela, 15HUC, Caracas,
Venezuela, 16Clinica Santa Soﬁa, Caracas, Venezuela, 17hospital de Clinicas
Caracas, caracas, Miranda
Background: Catheter-based renal denervation (RDN) had shown to be an effective
treatment to control blood pressure (BP) in patients with resistant hypertension. In the
Symplicity HTA-2 randomized controlled trial, RDN lowered systolic blood pressure
by 32  23 mmHg. In addition, radiofrequency (RF) ablation of renal arteries reducesJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrsympathetic activity reducing left ventricular mass and insulin resistance. However,
the efﬁcacy of this novel procedure in the real world clinical practice is still unknown.
Methods: Prospective, multicenter, observational registry of consecutive patients
submitted to RDN at 20 centers in Venezuela between February and December 2012.
We included patients with resistant hypertension deﬁned as systolic BP > 160 mmHg
despite taking three or more antihypertensive drugs with normal renal function
(estimated glomerular ﬁltration rate > 45 ml/min/1.73 mts2). The primary end-point
was reduction in systolic BP at 1 and 6 months follow-up, the secondary end-point
was any adverse event after the procedure.
Results: One hundred patients were included for this analysis; mean age was 54.9 
11, 46% were females, 49% caucasians and 33% diabetics. Pre-procedural ofﬁce BP
was 173/99 mmHg (SD 20/14), the mean number of anti-hypertertensive medica-
tions was 4.3 (85% diuretics with 23% aldosterone antagonist). Regarding proce-
dural characteristics 9.9  1.9 RF ablations were done per patient, with a mean
impedance reduction of -13.8%. At 30 days ofﬁce BP reduction was –33/17 mmHg
(SD 22/15 p¼0.002) and at 6 months (n¼75) –32/15 mmHg (p¼0.004). One
intraprocedural renal artery dissection occurred before radiofrequency energy
delivery that required no additional treatment and there were no adverse events
during follow-up.
Conclusions: Catheter-based RDN effectively reduces BP in the real world scenario
with this beneﬁts maintain at 6 months follow-up. In this preliminary experience, no
major complication was observed.
TCT-488
ALSTER-BP Registry: Follow up data from 100 patients including ﬁrst re-do
procedures
Lukas Kaiser1, Thomas Beister1, Andrea Wiese1, Felix Meincke1, Jasper von Wedel1,
Andreas Busjahn2, Karl-Heinz Kuck1, Martin W. Bergmann1
1Asklepios Klinik St.Georg, Hamburg, Germany, 2HealthTwiSt GmbH, Berlin,
Germany
Background: Renal denervation has gathered great impact as additional therapy
option for patients suffering from resistant hypertension. Here we report results of the
ALSTER-BP registry including 6 month follow up data from 93 patients that were
treated with renal denervation in real world setting. Additionally 8 patients underwent
a second renal denervation procedure and were followed up again.
Methods: Patients matching the established inclusion criteria for renal denervation
were included in the ALSTER-BP registry (n¼93) and were then treated with the
Symplicity renal denervation system. The follow-up period was 6 months. 8 patients
who showed no or insufﬁcient blood pressure reduction underwent a second renal
denervation procedure (re-do) 9 months after the ﬁrst procedure and were followed up
for another 6 months.
Results: The initial patient cohort (n¼93) was divided into three groups. Early
responders showed a reduction of ofﬁce systolic blood pressure >10mmHg 3 months
after the procedure (n¼53, 57%), late responders 6 months after the procedure (n¼16,
17%) and non-responders showed no signiﬁcant reduction (n¼24, 26%). After six
months systolic blood pressure was lowered by 462.9 mmHg (meanSEM,
p<0.001), 313.4mmHg (p<0.001) and 7.13.3mmHg (p¼0.79, ns), respectively.
Ambulatory blood pressure monitoring also showed a signiﬁcant reduction in the early
responder group (205.7mmHg, p¼0.002). In 5 out of 8 patients (63%) who
underwent a re-do procedure ofﬁce systolic blood pressure was lowered >10mmHg 6
month after the second procedure. One patient (13%) showed a signiﬁcant renal artery
stenosis that was treated by stent implantation 5 months after the second procedure.
No other adverse side effects were observed in all other patients.
Conclusions: Renal denervation is a safe and effective therapy option even in clinical
all day setting. There might be different mechanisms underlying the observed blood
pressure reduction that ﬁnd their expression in different response rates. The success of
the re-do procedure in 63% of the patients argues in favour of current ablation
techniques to not sufﬁciently reduce sympathetic innervation of the kidney to affect
blood pressure regulation in some patients.
TCT-489
Comparison Of Arterial, Surrounding Soft Tissue And Nerve Damage With
Irrigated Vs. Non-irrigated Radiofrequency Ablation
Kenichi Sakakura1, Elena Ladich1, Kristine Fuimaono2, Debby Grunewald2,
Patrick O'Fallon2, Fumiyuki Otsuka1, Kazuyuki Yahagi1, Frank D. Kolodgie1,
Renu Virmani1
1CVPath Institute, Inc., Gaithersburg, MD, 2Cordis/Biosense Webster, Inc. a Johnson
& Johnson Company, Irwindale, CA
Background: The effectiveness of radiofrequency (RF) ablation of renal autonomic
nerves has been proven. However, long-term safety of the renal artery (RA) is of
concern. The aim of our study was to determine if cooling during RF ablation
preserved the RA while allowing equivalent nerve damage.
Methods: A total of 10 swine with 20 RAs were enrolled, and relegated to the irri-
gated 50C (n¼6), non-irrigated 65C (n¼6), non-irrigated 90C (n¼6), and control
(n¼2) groups. Each RA was treated with RF ablation catheter (RenLane Renal
Denervation Catheter [Cordis, Inc. Fremont, CA, USA]) with different treatment
protocol as above. Animals were harvested at 10 days. RAs were serially sectioned,
and stained with H&E and Movat Pentachrome.acts/POSTER/Renal Denervation B149
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media injury was signiﬁcantly less in the irrigated 50C group (depth; 3.1[2.5-3.5],
circ; 1.1[0.8-1.4], thinning; 32%) compared to the non-irrigated 65C (depth; 3.5[3.1-
4], circ; 1.9[1.5-2.4], thinning; 79%) and 90C groups (depth; 4[3.5-4], circ; 3.4[2.7-
3.8], thinning; 90%) (depth; P¼0.04, circ; P<0.001, thinning; P¼0.01). Denatured
collagen was rarely observed in the irrigated 50C group (7%) compared to the non-
irrigated 65C (47%) and 90C groups (91%) (P¼0.001). Nerve damage was similar
between the irrigated 50C group (2.5 [2.1 to 3.2]) and 65C group (2.8 [2.6 to 2.9])
(P¼1.00).Pre RSD 6 months FU p-value
BP systolic (mmHg) 152  9 133  4 0.02
BP diastolic
(mmHg)
80  5 74  6 0.04
Ejection fraction
(%)
69.2  9 69.6  9 0.68
MPRI* 1.73 1.82 0.70
Septum basal
(mm)
11.40 10.78 0.02
Septum mid (mm) 9.03 8.75 0.03
Septum apical
(mm)
5.87 5.27 0.03
*myocardial perfusion reserve indexConclusions: Irrigation during RF ablation signiﬁcantly reduces arterial and peri-
arterial tissue injury, while effectively injuring the autonomic nerves.
TCT-490
Evaluation of Acute, Sub-acute, and Chronic Renal Artery Nerve Morphological
Changes Following Bipolar Radiofrequency Renal Denervation Treatment in the
Porcine Model
Meital Mazor1, Rose Baird2, James Stanley2
1Vessix Vascular, Laguna Hills, CA, 2CBSET, Inc., Lexington, MA
Background: Catheter-based percutaneous renal denervation has shown durable
blood pressure reductions in adult patients with resistant hypertension. The objective
of this study was to evaluate long-term changes in renal artery nerve morphology
induced by bipolar radiofrequency (RF) energy.
Methods: The Vessix System (Boston Scientiﬁc, Natick, MA) was used for the renal
denervation procedures. The system consists of a RF generator and a low-pressure
balloon catheter with an exterior array of bipolar RF electrodes mounted in an offset
helical pattern. Juvenile Yorkshire swine (N¼17) were treated bilaterally. Renal artery
nerves affected by RF treatment were evaluated at 14, 28, and 180 days post-treatment
using histopathologic methods to assess quantity, size, and morphological changes.
Results: At 14 days, susceptible nerves (nerves within the RF treatment zone)
exhibited primarily degenerative changes (eg, vacuolization, hypercellularity,
inﬂammatory inﬁltrates, hemorrhage), while at 28 and 180 days, susceptible nerves
exhibited chronic changes (eg, intra/peri-fascicular ﬁbrosis, axonal loss, nerve/
fascicular atrophy). The average total number of nerves per plane of treated arterial
segment was signiﬁcantly increased at 180 days relative to 14 and 28 days, while the
average number of susceptible nerves per plane remained relatively constant over
time. The percentage of susceptible nerves was signiﬁcantly reduced at 180 days
relative to 14 and 28 days. The percentage of small nerves steadily increased over time
with a concomitant decrease in the number of large nerves.
Conclusions: Bipolar RF energy has an acute injurious effect (degeneration, necrosis)
on the renal artery nerves, which progresses to a chronic reactive phase by 28 days
post-renal denervation and which is evident for up to 6 months post-treatment.
Although the cause for the apparent increase in total nerves and decrease in average
nerve size over time is uncertain, these results could potentially reﬂect the plasticity of
nerve growth associated with increased age and size of the animals, or compensatory
efforts at target (ie, renal) re-innervation (eg, collateral sprouting).
TCT-491
Renal Artery Denervation with a New Simultaneous Multielectrode Catheter for
Treatment of Resistant Hypertension: Results from the Symplicity Spyral
First-in-Man Study
Robert J. Whitbourn1, Scott Harding2, Martin T. Rothman3, Tony Walton4
1St. Vincent Hospital Melbourne, Melbourne, Australia, 2Wellington Hospital,
Wellington, New Zealand, 3Medtronic, Inc., Santa Rosa, CA, 4Alfred Hospital,
Melbourne, Victoria
Background: Renal denervation (RDN) with the Symplicity Flex catheter signiﬁ-
cantly reduces blood pressure (BP) in patients with treatment-resistant hypertension. A
new, multielectrode catheter designed to deliver radiofrequency energy simulta-
neously to 4 treatment sites was designed to reduce treatment time and resource use
while providing a safe and effective denervation procedure. The Spyral multielec-
trode renal denervation system features a unipolar array of 4 electrodes mounted onB150 JACC Vol 62/18/Suppl B j Octoba nitinol shaft in a spiral conﬁguration and deliver radiofrequency energy (1 minute
per artery) in a controlled conﬁguration.
Methods: This prospective, non-randomized, open label, ﬁrst in man feasibility study
will enroll 50 patients. The primary safety endpoint is acute procedure safety asso-
ciated with the delivery and/or use of the Spyral catheter. The primary effectiveness
endpoint is change in ofﬁce BP from baseline to six months. Included subjects must
have resistant hypertension deﬁned as an ofﬁce systolic BP of 160 mm Hg ( 150
mmHg for type 2 diabetics) despite adherence to an antihypertensive regimen of at
least 3 drugs (preferably including a diuretic). Exclusion criteria include type 1 dia-
betes, renal artery stenosis >50% or renal artery aneurysm, prior renal artery inter-
vention, or an estimated glomerular ﬁltration rate of < 45mL/min/1.73m2. Subjects
will be followed at 1, 3 and 6 months and yearly to 3 years post RDN.
Results: Baseline characteristics for 29 enrolled subjects include age 64 years, 66%
male and 41% with diabetes. Baseline BP is 182  16/94  11 mm Hg and the mean
number of antihypertensive drugs is 4.7  1.3. The change in ofﬁce-based BP at 1
month is -1621/712 mm Hg (p<0.001 for systolic BP, p¼0.002 for diastolic BP).
The total RDN procedure time was 21.2 7.7 minutes. There were 2 femoral artery
pseudoaneurysms. No new renal artery stenosis or hypertensive emergencies occurred.
Conclusions: RDN using the Spyral multielectrode catheter can be safely delivered
with a procedure time less than half that of the Symplicity Flex catheter. Further
procedural details and 3 month follow-up will be presented.
TCT-492
Renal sympathetic denervation: Does reduction of left ventricular mass translate
into improved intramyocardial perfusion?
Martin Schmidt1, Florian Roessner1, Uli Ebersberger2, Manuel Berger1,
Diethmar Antoni1, Uwe Dorwarth1, Johannes Rieber1, Ellen Hoffmann1
1Klinikum Bogenhausen, München, Germany, 2Klinikum Bogenhausen, München,
Germany
Background: Left ventricular (LV) hypertrophy is a common ﬁnding in patients with
resistant hypertension and is associated with an impaired intramyocardial perfusion.
Renal sympathetic denervation (RDN) has been shown to reduce blood pressure (BP)
and sympathetic tone. In this pilot study we aimed to investigate the effect of RDN on
LV wall thickness, myocardial function, and myocardial perfusion reserve at cardiac
magnetic resonance imaging (cMRI) in patients with resistant hypertension.
Methods: Resistant hypertension was deﬁned as mean systolic 24h BP > 145 mmHg
despite the use of at least 3 antihypertensive drugs. Adenosin-stress-induced cMRI
was performed at baseline, 3, and 6 months after RDN. RDN was performed bilat-
erally in the renal arteries using a single soft tip radiofrequency catheter (Symplicity,
Medtronic, U.S.).
Results: Six patients (5 males, 659 years) suffering from resistant hypertension,
despite the use of 51 antihypertensive drugs, were investigated. Resting systolic BP
signiﬁcantly decreased from 1529 mmHg to 1334 mmHg (p¼0.02), diastolic BP
from 804 mmHg to 746 mmHg (p¼0.04) at 6 months follow-up (FU). LV septal
wall thickness was signiﬁcantly reduced (basal 11.40 to 10.78 mm; p¼0.02, midseptal
9.03 to 8.75 mm; p¼0.03 and apical 5.87 to 5.28 mm; p¼0.03). No signiﬁcant
changes were found for LV ejection fraction and myocardial perfusion reserve index
at 6 months FU (Table).Conclusions: RDN signiﬁcantly reduced LV septal wall thickness as diagnosed by
cMRI, as well as systolic and diastolic BP. However, our pilot data do not show
a signiﬁcant change of the myocardial perfusion reserve. 6 months follow-up might
have been too short to lead to signiﬁcant changes in intramyocardial perfusion of
patients after RDN.er 27–November 1, 2013 j TCT Abstracts/POSTER/Renal Denervation
